INTRODUCTION {#sec1-1}
============

Leishmaniasis and malaria represent major public health problems with significant morbidity and mortality in Asia, Africa, and Latin America \[[@ref1],[@ref2]\]. Lack of vaccines, emergence of drug resistance, and expensive chemotherapeutics are some of the major challenges for the control of these vector-borne diseases, in addition to disadvantages including hospitalization for (parenteral) treatment, occurrence of adverse effects, long-term therapy leading to poor compliance and poor availability of drugs, especially to economically weak populations residing in rural areas \[[@ref3]-[@ref6]\].

Given the limited number of novel drugs in the pipeline and the expanding resistance against current drugs, it remains imperative to explore alternative ways to find new drugs. Plants contain a broad diversity of secondary metabolites such as alkaloids, flavonoids, and phenolic derivatives that may have therapeutic value, and hence may represent an attractive source for novel drugs \[[@ref7]\]. However, screening of each and every individual plant parts against wide range of pathogens is virtually impossible and plant selection based on ethnobotany and traditional practices, such as Ayurveda \[[@ref8]\], Unani, Siddha, traditional Chinese medicine, and Japanese Kampo medicine increases the probability of finding "hit" molecules that can be subsequently developed toward "lead" development \[[@ref9],[@ref10]\].

In Nepal, there is a huge variation in the number of medicinal and aromatic plants (MAP) \[[@ref11],[@ref12]\]. For example, compilation of the MAP database has listed 1624 medicinal plants in 2000 \[[@ref13]\], rising to 1950 species in 2008 \[[@ref14]\] clearly indicating that further exploration of the phytochemical and pharmacological properties of medicinal plants in Nepal should be continued. Up till now, very few indigenous Nepalese plants have been explored for their therapeutic potential against leishmaniasis and malaria. Starting from ethnobotanical literature and traditional use, the present study assessed the *in vitro* inhibitory activity potential of crude extracts of 29 selected Nepalese plants \[[Table 1](#T1){ref-type="table"}\], hence contributing to the medicinal knowledge of the local plant biodiversity.

###### 

List of the selected plants for this study, their phytoconstituents, and traditional uses
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MATERIALS AND METHODS {#sec1-2}
=====================

Plant Material {#sec2-1}
--------------

Leaves, twigs, aerial parts, and roots \[[Table 1](#T1){ref-type="table"}\] of selected plants were collected from different regions in Nepal \[[Figure 1](#F1){ref-type="fig"}\] from December 2013 to April 2014. All the collected plant materials were identified in the Department of Plant Resources, Nepal, and Voucher specimens are deposited in Pharmacognosy Unit of Department of Plant Resources, Thapathali, Kathmandu, Nepal (<http://www.dpr.gov.np>).

![Sampling site in Nepal for the collection of plant species](JIE-5-383-g002){#F1}

Extraction {#sec2-2}
----------

The plant materials were washed thoroughly with water and shade dried at room temperature. Dried samples were crushed into powder by electric blending and subjected to Soxhlet extraction using polar solvents (ethanol and methanol). The extracts were evaporated on a rotary evaporator under vacuum till a solid mass was obtained. The extracts were kept at 4°C until analysis. All the extracts were kept in sealed vials, labeled properly, and transported to the Laboratory of Microbiology Parasitology and Hygiene, University of Antwerp, for integrated *in vitro* screening.

Parasites and Cell Culture {#sec2-3}
--------------------------

Standard techniques were used as previously described \[[@ref9]\]. Briefly, *ex vivo* amastigotes of *Leishmania infant*um (MHOM/MA(BE)/67) were used for the *in vitro* antileishmanial assay. The strain was routinely passed in Syrian Golden hamsters every 6-10 weeks. The chloroquine (CQ)-resistant *Plasmodium falciparum* (K1 strain) was used for *in vitro* antiplasmodial activity testing. The human lung fibroblast cell line MRC-5 was cultured in minimum essential medium supplemented with 20 mM L-glutamine, 16.5 mM NaHCO~3~, and 5% fetal calf serum.

Biological *In Vitro* Assays {#sec2-4}
----------------------------

The integrated panel of microbial screens and standard screening methodologies were adopted as previously described \[[@ref9]\]. Plant extracts were tested at dilutions ranging from 128 to 0.25 µg/mL using automated robotics with a 10-fold serial dilution strategy. Initially, 2-fold serial dilutions were made in 100% dimethyl sulfoxide (DMSO) to ascertain complete solubility during the dilution process. An immediate dilution step was performed in Milli-Q water before transferring the respective compound dilutions to the test plates (1/20 dilution: 10 µL compound solution +190 µL cell medium and test system) so that the final in-test concentration of DMSO did not exceed 1%.

Antileishmanial Activity {#sec2-5}
------------------------

Mouse macrophages were stimulated by intraperitoneal injection of starch. 2 days after injection, macrophages were collected and seeded in each well (3 × 10^4^) of a 96-well plate. The plates were incubated at 37°C and 5% CO~2~. After 2 days of outgrowth, *ex vivo* amastigotes were used to infect primary peritoneal mouse macrophages at a 10:1 infection ratio. The plates were further incubated for 2 h before the compound dilutions were added. After 5 days of incubation, cells were dried, fixed with methanol, and stained with 20% Giemsa to assess total intracellular amastigote burdens through microscopic reading. The results are expressed as the percentage reduction of amastigote burden compared to untreated control cultures and inhibitory concentration 50% (IC~50~)-values were calculated.

Antiplasmodial Assay {#sec2-6}
--------------------

CQ-resistant *P. falciparum* 2/K 1-strain was cultured in human erythrocytes O^+^ at 37°C under microaerophilic atmosphere (3% O~2~, 4% CO~2~, and 93% N~2~) in RPMI-1640 supplemented with 10% human serum. 200 µL of infected red blood cells (1% parasitemia and 2% hematocrit) was added in each well of a 96 well plate containing prediluted extract. The test plates were kept in the modular incubator chamber for 72 h at 37°C, and subsequently, put at −20°C to lyse the red cells upon thawing. Next, 100 µL of Malstat™ reagent was put in new microtiter plate to which 20 µL of hemolyzed parasite suspension was added. After 15 min incubation at room temperature, 20 µl of nitro blue tetrazolium/polyethersulfone solution was added. The plate was incubated in the dark for another 2 h at room temperature and spectrophotometrically read at 655 nm. The IC~50~ was calculated from the drug concentration - response curves. According to the WHO guidelines (\[[@ref45]\]), antiplasmodial activity is very good with IC~50~ \<1 µg/ml; good to moderate if IC~50~ of 1-10 µg/ml; weak if 15-50 µg/ml, and inactive if IC~50~ \>50 µg/ml, always taking into account a selectivity index (SI) higher than 10.

RESULTS {#sec1-3}
=======

Antileishmanial Activity {#sec2-7}
------------------------

Only one plant extract (*Ampelocissus tomentosa)* exhibited moderate activity against *L. infantum* with an IC~50~ value of 13.2 ± 4.3 µg/ml and an SI value \>3. *Paris polyphylla* also showed inhibitory activity but was also cytotoxic \[[Table 2](#T2){ref-type="table"}\].

###### 

Antiprotozoal activity of extract of selected plants of Nepal and their cytotoxicity against MRC-5 cell lines
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Antiplasmodial Activity {#sec2-8}
-----------------------

Three plant species, *Phragmites vallatoria, A. tomentosa*, and *Terminalia chebula* showed schizonticidal activity. Among them, *T. chebula* exhibited the best activity with IC~50~ values of 4.5 ± 2.4 µg/ml and SI values \>5.

Cytotoxicity {#sec2-9}
------------

*Kalanchoe pinnata, P. polyphylla*, and *Pedilanthus tithymaloides* were toxic to the MRC-5 cell line. *K. pinnata* was most toxic with cytotoxic concentration 50% value of 4.7 ± 1.8 µg/ml.

DISCUSSION AND CONCLUSION {#sec1-4}
=========================

Leishmaniasis and malaria continue to be major public health problems, and the available drugs are generally expensive and not devoid of toxic side effects. Associated with poor compliance, the threat of drug resistance is also an emerging issue. Despite different strategies such as drug repurposing, identifying new therapeutic targets by chemoinformatics or screening diverse libraries of natural products, no new drugs have reached the market during the last decade. The present study was carried out to explore the potential of Nepalese medicinal plants that are used as part of traditional medicine. Nepal is very rich in biodiversity, which has not yet been explored satisfactorily due to the geopolitical situation, the lack of sophisticated labs, and the availability of trained manpower in industry and academics. The selected medicinal plants were screened against protozoal diseases using a "whole-cell based" approach, which can be considered more valid than enzyme-based subcellular approaches \[[@ref9]\].

In the present study, *A. tomentosa* showed selective antileishmanial (IC~50~ 13.2 ± 4.3 µg/ml) and antimalarial (11.7 ± 3.5 µg/ml) activity. To our knowledge, the antiprotozoal activity of this plant has never been investigated, and no active constituents have been documented in the literature. Further studies on bioassay-guided fractionation to identify the putative active constituents and to better understand the therapeutic targets will be necessary, including a screening of other species of *Ampelocissus* genus.

Likewise, good antimalarial activity was found for *T. chebula* and *P. vallatoria* with an IC~50~ of 4.5 ± 2.4 and 12.0 ± 7.5, respectively, and SI of \>5. This is the first observation that *P. vallatoria* showed potential activity against *Plasmodium*. The antiplasmodial activity of *T. chebula* has already been reported \[[@ref22]\] with an IC~50~ = 4.76 µg/mL against the CQ-sensitive (3D7) strain of *P. falciparum*, hence supporting its use in traditional medicine.

*P. tithymaloides* was also found to be active against *Leishmania* but was not totally devoid of cytotoxicity. In traditional medicine, *P. tithymaloides* is been used in treating multiple diseases (from antimicrobial to anticancer) related to the diverse phytoconstituents \[[Table 1](#T1){ref-type="table"}\]. The antiprotozoal activity of this plant might be due to the presence of a diterpene, as species belonging to the family Euphorbiaceae are rich in diterpenoids and triterpenoids \[[@ref46]\]. In previous studies, various poly-O-acylated jatrophane diterpenoids have shown *in vitro* antiplasmodial activity with IC~50~ values of 3.4-4.4 µg/ml, which has been confirmed *in vivo*, with 76% suppression of parasitemia in *P*. *berghei* infected mice \[[@ref47],[@ref48]\]. Likewise, diterpenes such as jatrogrossidione and jatrophone have been found to have toxic effects against promastigotes of *L. braziliensis*, *L. amazonensis*, and *L. chagasi* with IC~50~ in the range of 0.75-5 µg/ml \[[@ref49]\]. The moderate cytotoxic nature of *P. tithymaloides* might be due to the presence of pedilstatin or eurphorbol, which have already been established as irritants and carcinogens \[[@ref50]\].

Non-selective antileishmanial activity was shown for *P. polyphylla* and *K. pinnata*. *P. polyphylla* is known as "*satuwa"* and is traditionally used as anthelmintic and for reducing fever in the Himalayan region of Nepal. Our findings on cell toxicity of some plant extracts (IC~50~ 15 µg/ml) warrants for some vigilance as sometimes misleading information like "natural products are always safe" could eventually lead to deleterious health if high doses of these plants are consumed for a long time. Quite a lot of published literature indeed lacks parallel cytotoxicity evaluation. For example, *P. polyphylla* diosgenin-type saponins revealed antileishmanial activity (IC~50~ 1.6 µg/ml) but without parallel cytotoxicity evaluation \[[@ref42]\]. In our study, *K. pinnata* was highly cytotoxic (4.7 ± 1.8 µg/ml) while published data support that *K. pinnata* may possess immunosuppressive effects and inhibit disease progression in *L. amazonensis*-infected individuals \[[@ref31],[@ref51],[@ref52]\]. The same research group more recently reported that this plant possessed immunomodulatory activity and highlighted that oral dose of *K. pinnata* extract (400 mg/kg) is comparable to Pentostam^®^ (72 mg/kg) in reducing the hepatic and splenic parasitic burden \[[@ref53]\].

Further research on these plants should now focus on the structural elucidation of the putative "active constituents," *in vitro* evaluation using preset IC~50~ and SI cut-offs and *in vivo* evaluation in murine pharmacology models for pharmacokinetic and dynamic profiling.
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